FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

FDA approves bimonthly dosing regimen for Ebglyss in adults, children with eczema

The FDA approved a regimen of one maintenance dose every 8 weeks for lebrikizumab-lbkz in adults and children aged 12 years and older who weigh at least 88 pounds with moderate to severe atopic dermatitis, according to…